Altimmune is trading at $2.31, down 5.14%, with no new company-specific headline identified for October 14. - Broad market pressure followed hotter-than-expected September inflation, which renewed concerns about interest rates. - The biotech sector declined 2.01%; available sources do not establish a specific Altimmune catalyst or confirm the direct cause of its intraday move.